Linifanib is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in Aml) patient cells via reduction of AKT and GSK3β phosphorylation and maybe influential in Aml therapy.
Product Details
| Alternative Name: | A-741439, ABT-869, RG3635, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N’-(2-fluoro-5-methylphenyl)-urea |
| |
| Formula: | C21H18FN5O |
| |
| MW: | 375.4 |
| |
| CAS: | 796967-16-3 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | Brown powder. |
| |
| Solubility: | Soluble in DMSO (75mg/ml) or ethanol (5mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
